科创创新药ETF汇添富（589120）标的指数成分股多数冲高，荣昌生物、百利天恒涨超5%，百济神州涨超4%，泽璟制药、博瑞医药等涨幅居前， 特宝生物、益方生物等小幅回调。 【科创创新药ETF汇添富（589120）标的指数前十大成分股】 | 序号 | 代码 | 名称 | 申万一级行业 | 涨跌幅 | 估算权重 | | --- | --- | --- | --- | --- | --- | | 1 | 688235 | J-Z**KD | 医药生物 | 4.04% | 10.43% | | 2 | 688578 | 艾力斯 | 医药生物 | 0.82% | 9.10% | | 3 | 688506 | 百利天恒 | 医药生物 | 5.10% | 7.89% | | র্ব | 688180 | 君实生物-U | 医药生物 | 1.10% | 6.70% | | 5 | 688331 | 荣昌生物 | 医药生物 | 5.51% | 6.35% | | 6 | 688266 | 泽昌制药-U | 医药生物 | 3.74% | 6.07% | | 7 | 688166 | 博瑞医药 | 医药生物 | 2.27% | 4 ...

行 业 及 产 业 美容护理 2026 年 02 月 10 日 雅诗兰黛在华业绩双位数增长，1 月天猫美妆 业 研 究 / 行 业 点 评 证 券 证券分析师 王立平 A0230511040052 wanglp@swsresearch.com 王盼 A0230523120001 wangpan@swsresearch.com 聂霜 A0230524120002 nieshuang@swsresearch.com 联系人 王立平 A0230511040052 wanglp@swsresearch.com 本期投资提示： 研 究 报 告 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 中庚基金 使用。1 ⚫ 本阶段化妆品医美板块表现强于市场。2026 年 1 月 30 日至 2026 年 2 月 6 日期间， 申万美容护理指数上涨 3.7%，表现强于市场。其中，申万化妆品指数上涨 2.8%，强于 申万 A 指 4.4pct；申万个护用品指数上涨 0.7%，强于申万 A 指数 2.2pct。 ⚫ 周观点：雅诗兰黛在华业绩双位数增长，1 月天猫美妆品类高增。据雅诗兰黛 25Q4(FY26Q2) ...

穆迪：将艾伯维评级上调至A2，展望稳定。 来源：滚动播报 ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. With quarterly earnings underway, BioPharma Dive is providing a snapshot of some companies’ results and how they’re being received by investors. Today, we’re offering insight into the latest numbers from Bristol Myers Squibb, GSK and AbbVie. AbbVie angst AbbVie reported $16.6 billion worth of net revenue in the final three months of 2025, a 10% year-over-yea ...

Market Overview - Stock futures are mixed, showing signs of stabilization after a downturn in software and AI-related technology stocks, leading some investors to view the selloff as a buying opportunity [1] - Defensive sectors and commodity-linked assets are gaining interest, particularly as gold prices have risen above $5,000 per ounce, indicating strong demand for safe havens amid market uncertainty [1] Pre-Market Trading - In pre-market trading, S&P 500 futures rose by 0.11%, Nasdaq futures fell by 0.34%, and Dow futures increased by 0.22% [2] Company Movements - Silicon Labs (SLAB) shares surged by 49% following a definitive agreement for acquisition by Texas Instruments (TXN) at $231 per share in an all-cash transaction [3] - Texas Instruments (TXN) shares declined by 3% after announcing the acquisition of Silicon Labs [6] - Other notable stock movements include Eli Lilly (LLY) up 9%, Johnson Controls (JCI) up 5%, and AMD (AMD) down 10% [6]

It has been quite a while since I've covered AbbVie Inc. ( ABBV ). Back in August of last year, I initiated coverage with a buy rating as earnings were strong and their RinvoqI'm a full-time investor with a strong focus on the tech sector. I graduated with a Bachelor of Commerce Degree with Distinction, major in Finance. I'm also a proud lifetime member of the Beta Gamma Sigma International Business Honor Society. My core values are: Excellence, Integrity, Transparency, & Respect. I always, to the best of m ...

Core Insights - AbbVie Inc. (ABBV) was previously covered with a buy rating due to strong earnings and the performance of their drug Rinvoq [1] Company Overview - AbbVie Inc. is a pharmaceutical company that has shown strong earnings performance, which has positively influenced its stock rating [1] Analyst's Perspective - The analysis emphasizes the importance of constructive feedback to enhance the quality of investment insights [1]

It has been two years since I last covered AbbVie ( ABBV ) on Seeking Alpha. At that time, the stock had been stuck in a $130 to $170 range since 2022 on worries aboutI retired early after 22 years in the energy industry with roles in engineering, planning, and financial analysis. I have managed my own portfolio since 1998 and have met my goal to match the S+P 500 return over the long term with lower volatility and higher income. I mostly write on positions I already hold or am considering changing. I prefe ...

Core Insights - AbbVie (ABBV) stock has been trading in a range of $130 to $170 since 2022, primarily due to concerns regarding its future performance [1]. Group 1 - The author has not covered AbbVie for two years, indicating a significant period of observation without updates [1]. - The author has a long-term investment strategy, focusing on maximizing total return by purchasing stocks when they are undervalued relative to their intrinsic value [1]. Group 2 - The author holds a beneficial long position in AbbVie shares, indicating confidence in the company's future performance [2]. - The article reflects the author's personal opinions and is not influenced by any external compensation or business relationships [2].

Core Viewpoint - AbbVie Inc. is a leading biopharmaceutical company with strong financial performance in Q4 2025, driven by its immunology portfolio, and is projected to exceed profit expectations for 2026 [1][2][6] Financial Performance - AbbVie reported Q4 2025 sales of $16.62 billion, exceeding the consensus estimate of $16.42 billion, marking a 10% increase on a reported basis and a 9.5% increase operationally [2] - Adjusted earnings per share rose by 25.5% to $2.71, surpassing the expected $2.65 [2] Revenue Breakdown - The immunology portfolio generated global net revenues of $8.63 billion, reflecting an 18.3% increase, with Skyrizi sales up 32.5% to $5.01 billion and Rinvoq sales rising 29.5% to $2.37 billion [3] - Neuroscience sales climbed to $2.96 billion, a 17.9% increase, with Vraylar contributing $1.02 billion (up 10.5%) and Botox Therapeutics at $991 million (up 13.4%) [4] - The oncology portfolio saw a slight decline, generating $1.66 billion in sales, with Imbruvica's revenues down 20.8% to $671 million, while Venclexta's revenues increased by 8.6% to $711 million [4] Future Projections - AbbVie projects its 2026 profit to surpass Wall Street estimates, driven by strong sales of Skyrizi and Rinvoq [5][6] - The current stock price of ABBV is $216.97, reflecting a decrease of 3.85% or $8.69, with a market capitalization of approximately $383.47 billion [5]